Ascendis Pharma A/S (ASND) EPS Estimated At $-0.93

May 15, 2018 - By Adrian Mccoy

Analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to report $-0.93 EPS on May, 22.They anticipate $0.10 EPS change or 12.05 % from last quarter’s $-0.83 EPS. After having $-1.08 EPS previously, Ascendis Pharma A/S’s analysts see -13.89 % EPS growth. The stock decreased 0.53% or $0.35 during the last trading session, reaching $65.6. About 17,325 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 130.09% since May 15, 2017 and is uptrending. It has outperformed by 118.54% the S&P500.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 4 analysts covering Ascendis Pharma A\/S (NASDAQ:ASND), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ascendis Pharma A\/S had 11 analyst reports since November 17, 2017 according to SRatingsIntel. The firm has “Buy” rating by Credit Suisse given on Thursday, February 22. On Monday, February 26 the stock rating was maintained by Wedbush with “Buy”. The rating was maintained by Wedbush on Wednesday, April 4 with “Buy”. Credit Suisse maintained Ascendis Pharma A/S (NASDAQ:ASND) on Tuesday, March 20 with “Outperform” rating. J.P. Morgan maintained the shares of ASND in report on Wednesday, January 17 with “Buy” rating. As per Tuesday, February 6, the company rating was maintained by Wedbush. The stock of Ascendis Pharma A/S (NASDAQ:ASND) earned “Buy” rating by Wedbush on Friday, January 5. Bank of America maintained Ascendis Pharma A/S (NASDAQ:ASND) rating on Thursday, January 25. Bank of America has “Buy” rating and $60 target. The stock has “Buy” rating by Bank of America on Friday, November 17. The firm has “Buy” rating given on Monday, March 19 by Wedbush.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.72 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

More recent Ascendis Pharma A/S (NASDAQ:ASND) news were published by: Benzinga.com which released: “Top Ideas From The 2018 Sohn Conference: Box, Bitcoin, Facebook, Palo Alto And More” on April 23, 2018. Also Nasdaq.com published the news titled: “Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP” on May 08, 2018. Globenewswire.com‘s news article titled: “Ascendis Pharma A/S Announces Upcoming Investor Presentations” with publication date: April 25, 2018 was also an interesting one.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


WP Twitter Auto Publish Powered By : XYZScripts.com